View
Page
Northland Capital Partners published a note on Immupharma this morning, it's out on Research Tree: "Alto’s investment further corroborates our view that ImmuPharma represents a good investment opportunity. The group’s lead drug, a potential treatment for Lupus, currently in a Phase 3 clinical trial, is expected to deliver a pivotal read-out by the end of 2017..."
Latest from the Community...
Latest from the Community...
Latest from the Community...